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Objective: Serotoninergic neurotransmission may modulate b-amyloid peptide (Ab) metabolism through upregulation
of a-secretase. Early Parkinson disease (PD) shows variable serotoninergic denervation, which may impact Ab
deposition.
Methods: We conducted 3 analyses to explore associations between serotoninergic neurotransmission and cerebral
Ab burden in PD. The first was a cross-sectional imaging study of PD subjects (n5 23) using the serotoninergic trans-
porter positron emission tomography (PET) ligand [11C]3-amino-4-(2-dimethylaminomethyl-phenylsulfaryl)-benzonitrile
(DASB) and amyloid PET Pittsburgh compound B ([11C]PiB). The second was a baseline study of Parkinson’s Progres-
sion Markers Initiative (PPMI) subjects exploring the influence of serotoninergic medications on cerebrospinal fluid
(CSF) Ab-42 levels (n5 389), controlling for age, sex, Geriatric Depression Scale, disease duration, and education.
Third, we fit an interval censored proportional hazard model with longitudinal PPMI data (n5367) to test whether
serotoninergic medication use associates with reduced risk of PD cognitive decline, defined as time to reach a Mon-
treal Cognitive Assessment score20, adjusting for baseline caudate dopamine transporter [123I]ioflupane single
photon emission computed tomography and CSF Ab-42 levels.
Results: Serotoninergic DASB distribution volume ratio (DVR) inversely associated with PiB DVR in the cerebral cortex
(Pearson r520.478, p5 0.021) but not the striatum (r520.264, p50.224). In the baseline PPMI analysis, serotonin-
ergic medication use for 6 months associated with a lower level of CSF Ab-42 (t522.20, p5 0.029). In the longitu-
dinal PPMI model, baseline serotoninergic medication use associated with a reduced risk of cognitive decline
(t522.03, p5 0.043) after controlling for covariates.
Interpretation: Cortical Ab burden in PD associates inversely with serotoninergic innervation. Serotoninergic medica-
tions may alter Ab metabolism and reduce the risk of PD cognitive decline.
ANN NEUROL 2018;83:994–1002
Progressive cerebral b-amyloid peptide (Ab) plaqueburden is linked to clinically meaningful outcomes—
including cognitive decline1,2 and gait impairments3,4—
in Parkinson disease (PD) and synucleinopathy-associated
dementias. Ab plaque deposition, assessed by amyloid
positron emission tomography (PET), is associated with
prevalent cognitive impairment in parkinsonian condi-
tions.5 Reduced cerebrospinal fluid (CSF) Ab-42 oligom-
ers and factors influencing their metabolism are also
consistently reported as risk factors for subsequent cogni-
tive decline in PD without dementia.6–8 Developing
strategies to alter the natural history of Ab burden in PD
may represent an untapped disease-modifying approach
and is an emerging research priority.
Variable loss of serotoninergic nerve terminals in
the forebrain, striatum, and brainstem is described in
PD.9,10 Significant loss of serotoninergic terminals is an
early feature in a substantial fraction of PD subjects.7,8
Preclinical experiments in Alzheimer disease (AD) mouse
models by Cirrito et al showed that chronic exposure to
either serotonin itself or the selective serotonin reuptake
inhibitor (SSRI) citalopram reduced extracellular cerebral
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Ab peptide concentrations and plaque burden in short-
and long- term in vivo studies.11,12 Serotonin and SSRIs
are suggested to stimulate a serotonin G-protein–coupled
receptor–linked intracellular cascade that favors the cleav-
age of amyloid precursor protein (APP) by a-secretase,
leading to reductions in toxic Ab peptide amyloid gener-
ation and reduced plaque formation.11 Serotonin medica-
tions may also promote efflux of toxic Ab peptide species
from the brain into the blood.13 Other preclinical
research supports the concept that serotoninergic neuro-
transmission can favorably modulate APP process-
ing.14–17 If the same protective association between
serotonin receptor activation and reduced amyloid bur-
den exists in humans, a disease state such as PD with
reductions in serotoninergic tone offers a potential model
for testing this hypothesis. In a small cohort, we previ-
ously reported that regional density of cortical and stria-
tal serotoninergic terminals in PD, measured by in vivo
PET, showed inverse correlations with Ab plaque
burden.18
We present 3 analyses exploring associations
between serotoninergic neurotransmission and Ab burden
in PD, using different experimental designs to address 3
related hypotheses. First, using an identical multimodal
imaging approach to our earlier study in a new cohort,
we sought to replicate our findings that decreased cortical
serotoninergic innervation is inversely associated with the
severity of cortical Ab plaque burden in PD. Second,
using baseline data from the multicenter Parkinson’s
Progression Markers Initiative (PPMI), we explored asso-
ciations between serotonin medication use and CSF Ab-
42 levels. Third, we conducted a longitudinal analysis of
PPMI data to test whether baseline serotoninergic medi-
cation use associates with a protective effect on cognitive
decline in PD, independent of existing heterogeneity in
caudate dopamine transporter binding or baseline cere-
bral amyloid burden.
Patients and Methods
Study 1: Cross-Sectional Prospective PET
Imaging Study
In a previous PD cohort (n5 13), we reported inverse associa-
tions between cortical and striatal serotoninergic terminal and
amyloid PET findings.18 To determine whether these findings
were due to cohort-specific effects, we conducted a separate
cross-sectional multimodal PET imaging study of 23 PD sub-
jects. Inclusion criteria included age 45 years, a diagnosis of
PD as determined by the UK Parkinson’s Disease Society Brain
Bank Clinical Diagnostic Criteria,19 no evidence of atypical
parkinsonism or neuroleptic-associated PD, no contraindica-
tions to undergoing magnetic resonance imaging (MRI) such as
indwelling metal hardware in the body, and no exposure to
serotoninergic medications, anticholinergic medications, or cho-
linesterase inhibitors in the last 2 months. This study was
reviewed by the institutional review boards of the University of
Michigan Medical School (IRBMED), and all subjects signed
informed consent prior to study enrollment.
Regional serotonin terminal density was assessed with the
serotonin transporter PET ligand [11C]3-amino-4-(2-dimethyla-
minomethyl-phenylsulfaryl)-benzonitrile (DASB), and cerebral
amyloid plaque deposition was measured with [11C]Pittsburgh
compound B (PiB) PET as described previously.18 For 22 of
the 23 subjects, all MRI, DASB, and PiB PET scans took place
within 1 week of each other. In 1 subject, the DASB and PiB
scans were separated by 41 days. All PET studies were per-
formed with bolus and infusion dynamic imaging protocols.
Cortical and subcortical segmentation was performed with Free-
Surfer version 5 in the fully automated mode. All image frames
were spatially coregistered within participants with a rigid-body
transformation. Motion-corrected PET frames were spatially
coregistered to the T1-weighted MRI using standard coregistra-
tion procedures in NeuroStat (https://neurostat.neuro.utah.edu/).
Time activity curves for each volume of interest were generated
from the spatially aligned PET frames. DASB and PiB distribu-
tion volume ratios (DVRs) were estimated by the Logan plot
graphical analysis method20 with the time–activity curves as the
input function and with the inferior posterior cerebellum as refer-
ence tissue for both PiB and DASB. Pearson correlation coeffi-
cients were used to assess the relationship of PiB and DASB
DVRs in the total cortical and striatal regions of interest. Using
subject age, disease duration, years of education, and cortical
DASB DVR as covariates, we also conducted a multivariate linear
regression model with cortical PiB DVR as the outcome variable
and a covariate significance level for retention in the final model
of 0.1 using a backward-selection process. Interaction terms were
tested in the covariates retained in the final model and were
included at a p value threshold of 0.1.
Study 2a: Cross-Sectional PPMI Baseline
Analysis
The PPMI is a multicenter longitudinal observational study of
PD (http://www.ppmi-info.org/). Curated PPMI datasets con-
taining Ab-42 measurements, primary diagnoses, and dopamine
transporter (DaT) [123I]ioflupane single photon emission com-
puted tomography (SPECT) results were downloaded on
August 22, 2017. Datasets containing demographics and clini-
cal nonmotor testing were downloaded between October 10,
2016 and January 13, 2017. PPMI subjects underwent screen-
ing evaluations (month 0), followed by baseline evaluations
(typically at month 1), visit 1 evaluations (month 4), and sub-
sequent evaluations on a scheduled basis—initially at 3-month
intervals and then at 6-month intervals after visit 4 (month
13)—through a possible visit 12 (month 61). All subjects
signed informed consent upon enrollment into the PPMI. This
project, using publicly available coded PPMI data, was granted
not-regulated status by the the University of Michigan
IRBMED. Analyses were conducted in Stata 15 (StataCorp,
College Station, TX) and SAS 9.4 (SAS Institute, Cary, NC).
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Eligible subjects for our baseline analyses were those who
were coded as having a primary study diagnosis of “idiopathic
PD” at the time of screening visit, who had a screening visit
DaT scan evaluation, who had CSF Ab-42 tested at the baseline
visit, documentation of serotonin medication use at the time,
and who did not accrue an alternative primary study diagnosis
at a subsequent study visit. Figure 1 provides an overview of
our PPMI study cohorts. We categorized serotoninergic medica-
tions to include SSRIs,21 serotonin–norepinephrine reuptake
inhibitors (SNRIs),22 tricyclic antidepressants (TCAs),17 bupro-
pion,23 lithium,24 and St John’s wort,25 given that each of these
compounds has been shown to influence serotoninergic neuro-
transmission. In this cross-sectional baseline study aimed at
understanding the influence of serotonin medications on CSF
Ab-42, we categorized subjects as those taking serotonin medi-
cations for 6 months (n5 45) versus others (n5 344). Sero-
tonin medication use was treated as a categorical variable (yes/
no) and was not adjusted for dosing or weight. Age was defined
as the difference between year of birth and year of study enroll-
ment, and disease duration was defined at the number of years
between when symptoms were first noticed by the subject and
year of study enrollment. CSF Ab-42 levels26 were measured at
the baseline visit.
Baseline CSF Ab-42 was treated as the outcome variable
of interest in a multivariate linear regression using baseline
cross-sectional PPMI data. Covariates included serotonin medi-
cation use, age, sex, disease duration, self-reported years of edu-
cation, and baseline Geriatric Depression Scale (GDS) score on
the 15-item GDS. We aimed to control for the degree of
depressive symptoms using the GDS because late-life depression
is known to associate both with dementia risk and with CSF
Ab-42 burden.27,28 We controlled for years of education to
account for the possibility that subjects receiving prescription
serotonin medications might have unmeasured differences in
socioeconomic status relative to those not on serotonin
medications.
Study 2b: Longitudinal PPMI Proportional
Hazard Analysis
We conducted a survival analysis in the PPMI cohort to explore
the effects of serotoninergic medications on cognitive decline in
PD. PD subjects who had 2 Montreal Cognitive Assessment
(MoCA) scores recorded over the duration of the study, who
underwent DaT SPECT at screening, and who had a screening
MoCA score of >20 at study entry were eligible for inclusion
(see Fig 1).
We chose progression to MoCA scores of 20 as our
endpoint, given that this transition value (21!20) has been
previously validated against full neuropsychological testing in
PD as an optimal diagnostic cutoff point (as opposed to a
“screening” cutoff value) for meeting neuropsychological criteria
of impairment in at least 2 cognitive domains suggestive of
dementia.29 We aimed to define our MoCA endpoint as mani-
festation of a clear stage-progression milestone, and tried to dif-
ferentiate this endpoint from a transient drop in scoring that
might improve at the next visit. Subsequently, we defined our
endpoint as having been met if a subject had 2 consecutive
visits with MoCA scores 20 or if their final recorded MoCA
score was 20. We qualified time to event as the month corre-
lating with the planned visit according to the PPMI schedule of
activities: screening visit (month 0), visit 4 (month 13), visit 6
(month 25), visit 8 (month 37), visit 10 (month 49), through
visit 12 (month 61). To account for the possibility of missed
study visits and the likelihood of that not all study visits took
place at the identical time interval, we conducted a survival
analysis using interval censoring with a Weibull proportional
hazard distribution. Subjects whose MoCA scores progressed
from >20 at screening visit (month 0) to  20 by visit 4
(month 13) were identified as having progressed to the MoCA
endpoint in an interval between 1 and 13 months and were cat-
egorized as interval censored rather than left censored. All other
subjects who did not progress to a MoCA score of 20 or less
were considered right censored at the time of their final
recorded MoCA score. Of note, an inclusion criterion for
enrollment in the PPMI was that subjects were “not expected
to require PD medication within at least 6 months from base-
line” (http://www.ppmi-info.org/study-design/).30 Subsequently,
none of our longitudinal PPMI subjects were on dopaminergic
PD medications at study enrollment.
We first tested the unadjusted bivariate associations
between several different potential explanatory variables includ-
ing the use of serotoninergic medications at the time of baseline
evaluation (Supplementary Table) in separate Cox proportional
hazard analyses. Next, we tested associations in a multivariate
model after adjusting for several baseline confounders. The
nigrostriatal dopaminergic system is known to play a role in
PD cognitive impairment, specifically dopamine terminal loss
in the caudate nucleus.31,32 We estimated this using mean bilat-
eral caudate nucleus DaT SPECT measurements from the
FIGURE 1: Diagram of subject selection from Parkinson’s
Progression Markers Initiative. CSF5 cerebrospinal fluid;
DaT5dopamine transporter; MoCA5Montreal Cognitive
Assessment; PD5Parkinson disease.
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PPMI.33 We sought to control for heterogeneity in baseline
amyloid status by using baseline CSF Ab-42 levels as a covariate
as well. Covariates were tested to explore the assumption of
proportional hazards. To test whether a serotonin-medication
effect on MoCA decline might vary across drug classes of differ-
ing specificity for serotonin-receptor modulation, we conducted
2 separate sensitivity analyses where the serotonin medication
use categorical variable was restricted to either only those sub-
jects taking SSRIs or those subjects taking either SSRIs or
TCAs.
Results
Demographic characteristics for the Study 1 cohort are
presented in Table 1. In the multimodal PET imaging
study, cortical serotoninergic terminal density correlated
inversely with cortical amyloid burden (Pearson
r520.478, p5 0.021; Fig 2). Striatal serotoninergic
terminal density did not significantly correlate with
striatal amyloid deposition (Pearson r520.264,
p5 0.224). In our multivariate linear regression model
of cortical PiB DVR, disease duration and cortical
DASB DVR were retained at a covariate threshold of
p< 0.1. The final model (F5 5.11, p5 0.0161) showed
an R2 of 0.338, with a significant association seen for
cortical DASB DVR (t5 8.13, p5 0.0099) and a
FIGURE 2: Cortical [11C]Pittsburgh compound B (PiB; amy-
loid) versus [11C]3-amino-4-(2-dimethylaminomethyl-phenyl-
sulfaryl)-benzonitrile (DASB; serotonin) positron emission
tomography distribution volume ratio (DVR; n523).
TABLE 1. Subject Characteristics
Characteristic Study 1: PD PET
Imaging Cohort
Study 2a: PPMI
Cross-Sectional
Baseline Cohort
Study 2b: PPMI
Longitudinal
Cohort
n 23 389 367
Baseline age, yr 66.2 (6.7) [48–79] 61.8 (9.6) [34–85] 61.7 (9.7) [34–85]
Male sex 17 (74%) 253 (65%) 238 (65%)
Disease duration, yr 4.9 (4.1) [1–12] 1.9 (2.0) [0–21] 1.9 (2.0) [0–21]
Hoehn and Yahr score HY15 6, HY25 15, HY35 2 HY15 191, HY25 198 HY15 180, HY25 187
Education, yr 16.9 (3.1) [12–25] 15.6 (3.0) [5–26] 15.5 (2.9) [5–26]
MoCA score at screening 25.6 (2.4) [20–29] 27.2 (2.3) [17–30] 27.2 (2.1) [21–30]
Final MoCA score at the time
of event/censoring
NA NA 26.4 (3.3) [15–31]
Mean absolute decline in MoCA
score between screening and final
score at the time of event/censoring
NA NA 0.8 (3.0) [26 to1 13]
GDS score at baseline 7.2 (4.5) [1–15]a 5.1 (1.6) [0–10] 5.1 (1.6) [0–10]
Cerebrospinal fluid Ab-42 levels at
baseline, pg/ml
— 371.5 (101.5) [129.2–796.5] 373.2 (102.2) [129.2–796.5]
Mean cortical amyloid PiB PET
distribution volume ratio
1.06 (0.021) [1.04–1.11] — —
Values are given as mean (standard deviation) [min–max] or count (%).
aThis score represents the 30-item GDS score, whereas the PPMI cohorts used the 15-item GDS.
GDS5Geriatric Depression Scale; MoCA5Montreal Cognitive Assessment; NA5 not applicable; PD5 Parkinson disease; PET5 positron emis-
sion tomography; PiB5 [11C]Pittsburgh compound B; PPMI5 Parkinson’s Progression Markers Initiative; HY5Hoehn and Yahr score.
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nonsignificant associative trend for duration of disease
(t5 3.32, p5 0.0836). There were no significant inter-
actions between cortical DASB DVR and disease
duration.
In Study 2a, subjects on serotonin medications for
at least 6 months at baseline (n5 45) did not differ
significantly in CSF Ab-42 levels from subjects not
receiving serotonin medications in unadjusted analyses
(mean6 standard error [SE]: 348.56 15.0pg/ml vs
374.56 5.5pg/ml; t5 1.62, p5 0.11). After adjusting
for confounders, the multivariate linear regression analy-
ses (n5 389; Table 2) showed that male sex and use of
serotonin medications for at least 6 months both associ-
ated with lower levels of CSF Ab-42 at baseline. Age,
disease duration, years of education, and GDS score did
not show significant associations.
A total of 367 subjects met inclusion criteria for
the survival analysis (Study 2b) predicting time to a
decline in MoCA score of 20. Of these 367 subjects,
70 (19.1%) were using serotoninergic medications at the
time of their baseline visit. Twenty-eight of the total 367
subjects progressed to develop an MoCA score of 20 as
assessed at a subsequent study visit. In a bivariate Cox
proportional hazard analysis, taking a serotoninergic
medication at baseline did not show a significant associa-
tion with decline to an MoCA of 20 (see Supplemen-
tary Table). Table 3 shows the results of a multivariate
interval censored model controlling for the confounder
effects of screening caudate nucleus DaT SPECT binding
ratio and baseline CSF Ab-42 levels. In this model, sero-
toninergic medication use at baseline showed a protective
association with reduced likelihood of MoCA decline.
Sensitivity analyses of this interval censored multivariate
model using different definitions of serotonin medica-
tions revealed comparable but nonsignificant trends
between both SSRI (n5 49 of 367, hazard ratio5 0.185,
SE5 0.189, 95% confidence interval [CI]5 0.025–
1.372, Z521.65, p5 0.099) use and/or the combina-
tion of either SSRI or TCA (n5 54 of 367, hazard
ratio5 0.170, SE5 0.173, 95% CI5 0.023–1.257,
TABLE 2. Baseline Parkinson’s Progression Markers Initiative Cross-Sectional Multivariate Linear Regression
Analysis (n5389)
Covariates Beta Standard
Error
t Score p 95% Confidence Interval
for Beta Values
Age in years 20.810 0.533 21.52 0.129 21.859, 0.238
Male sex 228.971 11.002 22.63 0.009 250.603, 27.338
Disease duration in years 1.241 2.533 0.49 0.625 23.740, 6.221
Years of education 0.067 1.718 0.04 0.969 23.311, 3.446
Geriatric Depression Scale-15 score 24.262 3.142 21.36 0.176 210.440, 1.915
Positive serotonin medication status
for 6 months
235.874 16.341 22.20 0.029 268.004, 23.745
Dependent variable: baseline cerebrospinal fluid Ab-42 (pg/ml); overall model F5 2.35, p5 0.0305.
TABLE 3. Study 2b Multivariate Proportional Hazard Model of Time to Reach Montreal Cognitive Assessment
Score of 20
Covariates Hazard
Ratio
Standard
Error
Z score p 95% Confidence Interval
for Hazard Ratio
Mean bilateral caudate DaT SPECT binding
ratio at screening
0.456 0.183 21.96 0.050 0.208, 1.000
Serotoninergic medication status at baseline 0.223 0.165 22.03 0.043 0.052, 0.952
Mean baseline Ab-42 in pg/ml 0.993 0.002 23.25 0.001 0.989, 0.997
Overall model likelihood ratio: chi-square5 22.70, p< 0.0001, 3 degrees of freedom.
DaT5 dopamine transporter; SPECT5single photon emission computed tomography.
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Z521.74, p5 0.083) use and the risk for MoCA
decline.
Discussion
We present findings from converging lines of evidence
supporting the hypothesized relationship between seroto-
ninergic neurotransmission and cerebral amyloid burden
in PD. Study 1 confirms our previous imaging findings
of a relationship between reduced serotonin terminals in
the cortex and the increased severity of cerebral amyloid
plaque burden in PD. Study 2a shows an association
between serotoninergic medication exposure for 6
months and lower CSF Ab-42 levels. Study 2b suggests
that serotoninergic medication exposure at baseline is
associated with a reduced risk for progression to a
MoCA score of 20. Collectively, these findings support
the concept that serotoninergic medications favorably
associate and/or alter cerebral Ab peptide activity in PD.
Postmortem studies of PD show reductions in sero-
tonin terminal markers in numerous cortical and subcor-
tical regions.34,35 Consistent with in vivo PET imaging
results, analysis of postmortem specimens by Buddhala
et al showed that serotoninergic terminal loss in PD
exhibits considerable variation, with many PD subjects
exhibiting regional serotonin terminal marker levels com-
parable to those found in control subjects and others
showing marked loss of serotonin terminal markers.34
PET studies suggest that regional serotonin terminal loss
is an early event in PD.10,36 This early and heteroge-
neous loss of serotoninergic terminals may suggest a pos-
sible causal role for serotoninergic modulation of Ab
peptide generation in PD, the latter of which is a later
stage disease feature that also shows substantial heteroge-
neity in cortical plaque burden.5 In contrast to our initial
findings, we did not find a significant correlation
between striatal DASB and PiB DVRs in the current
cohort. This may reflect stage-specific associations not
seen in our cohort, given that striatal amyloid burden
has been described more commonly in PD with
advanced cognitive impairment as opposed to early
PD.37,38 Within the range of values seen in our Study 1
cohort, however, disease duration did not appear to influ-
ence the association between cortical DASB and PiB
DVRs. Understanding temporal associations between
early regional serotonin terminal loss and progressive
amyloid plaque deposition leading to local neuronal dys-
function may be a fruitful goal for future PD natural his-
tory studies.
Our Study 2a analysis results indicating lower CSF
Ab-42 levels in PD subjects taking serotoninergic medi-
cations are consistent with recent preclinical and clinical
data suggesting that increasing serotoninergic
neurotransmission reduces Ab peptide generation. Cirrito
et al demonstrated that chronic oral administration of
citalopram relative to placebo in an AD mouse model
diminished extracellular Ab peptide levels and led to a
62% reduction in relative cortical amyloid plaque burden
after 4 months.11 In a retrospective analysis of 177
healthy controls, the duration of serotonin medication
exposure correlated with reduced cortical amyloid PET
binding.11 A separate prospective randomized trial of
young healthy adults showed that those receiving an
acute 60mg dose of citalopram rather than placebo expe-
rienced a 38% reduction over about 2 days in CSF Ab
peptide concentrations, and the kinetics of this reduction
was consistent with reduced Ab peptide generation.12
Although higher Ab-42 CSF levels are typically associ-
ated with better cognitive outcomes in PD, interpretation
of Ab-42 CSF level data is not straightforward.
CSF Ab-42 CSF levels likely reflect complex inter-
actions between Ab-42 peptide generation, clearance, and
possibly sequestration in amyloid plaques. Some evidence
suggests that reduced Ab-42 levels would be consistent
with reduced risk of dementia. In vitro data indicate that
the protective APP A673T mutation is associated with
reduced Ab-42 generation.39 Recent evidence from APP
A673T mutation carriers shows reduced serum levels of
Ab-42, which is expected to correlate with CSF Ab-42
levels.40 Similarly, increased Ab-42 generation is pre-
dicted to increase dementia risk. Statistical modeling of
CSF Ab-42 data from autosomal dominant AD (ADAD)
mutant allele carriers followed in the Dominantly Inher-
ited Alzheimer Network study suggests early elevation of
CSF Ab-42 levels followed by decline around the esti-
mated onset of manifest disease.41 In this model, declin-
ing CSF Ab-42 levels in ADAD subjects is secondary to
neurodegeneration causing diminished Ab-42 peptide
generation and/or Ab-42 peptide sequestration in amy-
loid plaques. The implication is that the association
between lower CSF Ab-42 levels and dementia risk is a
consequence of more advanced pathology.
Our finding (Study 2b) that baseline serotoninergic
medication exposure reduced risk of progression to
MoCA< 20 is also consistent with a beneficial modula-
tory effect of serotoninergic agents on Ab-42 peptide
generation. Similar results were reported recently in a ret-
rospective analysis of conversion from mild cognitive
impairment to dementia in the Alzheimer Disease Neu-
roimaging cohort.42 Antidepressant medications were also
suggested to reduce dementia incidence in analyses from
Kessing et al in datasets drawn from large Danish regis-
tries of prescription drugs.43,44 Our sensitivity analyses
did not show significant associations of SSRIs and SSRIs/
TCAs with time to MoCA decline. Given the relatively
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similar hazard ratios but increased hazard ratio SEs for
the serotonin medication use variable in these subgroup
analyses, these findings may be a manifestation of an
expected reduction in statistical power with fewer sub-
jects subsequently identified as having the exposure of
interest.45 Alternatively, they may reflect either the possi-
bility that nonserotonin neuronal systems are preferen-
tially involved in altering the risk of PD cognitive
decline or the possibility that only a low degree of sero-
tonin receptor modulation may be needed to yield a pro-
tective cognitive effect.
Serotoninergic medications are used early and often
in PD to treat symptoms of depression, anxiety, sleep
disorders, or other nonmotor features. In the PPMI
cohort, about 20% of subjects were on serotoninergic
medications at baseline. A community-based PD registry
study in Sweden estimated the rate to be 22% in home-
dwelling individuals and 50% in those residing in an
institution.46 To date, PD trials that have studied the
efficacy of SSRIs, SNRIs, or TCAs typically employed
relatively short study assessment periods (weeks to
months) focused on symptomatic modification of self-
reported affective symptoms and have not measured cere-
bral amyloid burden.47,48 One post hoc analysis of a
4-month randomized PD antidepressant trial showed no
clear benefit of paroxetine or nortriptyline on cognitive
performance relative to placebo but was limited to a
small sample size and short follow-up duration.49 The
possible beneficial effect of certain TCAs on amyloid-
linked cognitive decline may also be confounded by their
anticholinergic properties. A systematic review by
Moraros et al investigated the association between antide-
pressant drugs and dementia risk and found a higher
unadjusted dementia risk in subjects initiated on antide-
pressants before age 65 years.50 These findings are likely
to be influenced by the severity and variable causes of
comorbid depression. They do, however, raise the possi-
bility that there may exist a critical time window for
serotoninergic neurodegeneration-induced acceleration of
cerebral amyloid burden. This may be relevant for the
design of future interventional studies. Our Study 2b
clinical findings would benefit from validation not only
in other PD cohorts but also in prospective longitudinal
studies of aging that could control for drug class and
dosing.
Limitations of our study include the possibility of
differential censoring. Only a small fraction of eligible
subjects progressed to an MoCA score of 20, raising
the possibility that some subjects with declining cogni-
tion might have been lost to follow-up and would
thereby not be captured in this dataset. It is possible that
such censoring occurred and may influence these data.
Subjects enrolled in the PPMI may represent a skewed
population, given that their parkinsonian symptoms were
not severe enough to require the use of dopaminergic
medications at the time of enrollment. This cohort factor
may limit the generalizability of our findings. Because of
power concerns, we were not able to control for a greater
number of covariates, given the limited number of sub-
jects who did progress to the MoCA endpoint. Some
PPMI subjects showed variability in MoCA scoring from
one visit to the next. We chose our endpoint specifically
for the purpose of accurately identifying newly developed
probable dementia rather than as a screening cutoff for
subjects at risk for dementia. This effort to more pre-
cisely define a cognitive state transition point limited the
number of PPMI subjects who met our primary end-
point. This tradeoff, however, comes with improved pre-
cision as it relates to our assessment of baseline risk
factors associated with longitudinal cognitive decline.
Our previously published cross-sectional DASB-PiB PD
PET imaging cohort18 had an even higher mean age
(68.38 years) and lower mean MoCA (24.3) than the
23-subject imaging cohort in Study 1. In the present
analyses, subjects enrolled in Study 1 were older, had
longer disease duration, and had lower MoCA scores
than subjects in the PPMI. This may limit how translat-
able findings from Study 1 are to the cohort in Study 2
and vice versa. Conversely, these findings may also collec-
tively shed light into different aspects of the natural his-
tory of serotoninergic neurodegeneration across different
disease stages in PD.
We acknowledge that our findings do not directly
test the protective causal mechanism that we hypothesize
exists between serotoninergic medications, a-secretase
activity, and the degree of cerebral amyloid burden in
PD. It is possible that subjects in this cohort receiving
serotoninergic medications from their personal clinicians
may have other unmeasured factors that influence amy-
loid burden and/or cognition, including severity and sub-
types of affective symptoms or factors that associate with
greater access to care and prescription medications. Given
the wide variety, dosing, and duration of use of seroto-
ninergic medications by subjects, we were not able to
explore a dose–response relationship.
Developing treatments for different causes of cere-
bral amyloid burden is a goal relevant not only to PD
but to a majority of patients affected by neurodegenera-
tive diseases. Our PD findings are strengthened by the
multicenter nature of the PPMI but would benefit from
replication in other representative PD datasets. Seroto-
ninergic medications are well tolerated in PD patients,
and SSRIs targeted against cerebral amyloid burden merit
consideration for future PD clinical trials. Such trials
ANNALS of Neurology
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might be usefully enhanced by use of serotonin terminal
imaging to select or stratify the subject population.
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